Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer

14 Apr 2015

Abstract excerpt

// Agnieszka K. Witkiewicz 1,2 , Nicholas A. Borja 3 , Jorge Franco 1 , Jonathan R. Brody 4 , Charles J. Yeo 5 , John Mansour 2,3 , Michael A. Choti 2,3 , Peter McCue 4 and Erik S. Knudsen 1,2 1 Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA 2 Simmons Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA 3 Department of Surgery, UT Southwestern Medical Center, Dallas, TX, USA 4...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer Genomics and Diagnostics
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26158861
DOI: 10.18632/oncotarget.3819

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancerPMID 26158861Read ↗

Establishment and Thorough Characterization of Xenograft (PDX) Models Derived from Patients with Pancreatic Cancer for Molecular Analyses and Chemosensitivity TestingSemantic proximity Read ↗

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancerSemantic proximity Read ↗

A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.Semantic proximity Read ↗

Patient-derived organoids guide personalized therapy for KRAS-mutant pancreatic cancer: synergistic MEK/mTOR inhibition and predictive chemotherapy responses.Semantic proximity Read ↗

Generation and molecular characterization of pancreatic cancer patient-derived xenografts reveals their heterologous nature.Semantic proximity Read ↗

Unravelling the complexities of resistance mechanism in pancreatic cancer: Insights from in vitro and ex-vivo model systemsSemantic proximity Read ↗

Pancreatic cancer cell lines as patient-derived avatars: genetic characterisation and functional utility.Semantic proximity Read ↗

Navigating the complexities of pancreatic ductal adenocarcinoma: A review on therapeutic models and RAS inhibitors.Semantic proximity Read ↗

Clinical, molecular and genetic validation of a murine orthotopic xenograft model of pancreatic adenocarcinoma using fresh human specimens.Semantic proximity Read ↗

Patient-derived Tumor Xenograft and Organoid Models Established from Resected Pancreatic, Duodenal and Biliary CancersSemantic proximity Read ↗

Establishment of a novel human cell line retaining the characteristics of the original pancreatic adenocarcinoma, and evaluation of MEK as a therapeutic target.Semantic proximity Read ↗

Integrated Patient-Derived Models Delineate Individualized Therapeutic Vulnerabilities of Pancreatic CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.